ZOTA · Healthcare · Biotechnology
Composite scorecard: 32/100 — Quality 25 · Momentum 50
| Share price | ₹1,331.20 |
| Market cap | ₹4,316 Cr |
| P/B ratio | 13.8 |
| ROCE | -7.0% |
| Dividend yield | 0.07% |
| Book value | ₹103.04 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹539 Cr | ₹-74 Cr | 3.0% |
| 2025 | ₹292 Cr | ₹-57 Cr | -2.0% |
| 2024 | ₹180 Cr | ₹-14 Cr | 4.0% |
| 2023 | ₹139 Cr | ₹-6 Cr | 5.0% |
| 2022 | ₹131 Cr | ₹9 Cr | 11.0% |
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, health supplements, over-the-counter products, wellness and ayurvedic products, and nutraceutical products. It provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India.